{"id":771,"date":"2008-06-12T20:42:14","date_gmt":"2008-06-12T19:42:14","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=771"},"modified":"2013-08-28T06:58:53","modified_gmt":"2013-08-28T06:58:53","slug":"lower-bilirubin-increases-in-hcv-positive-patients-using-atazanavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/771","title":{"rendered":"Lower bilirubin increases in HCV-positive patients using atazanavir"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>A retrospective case note review of patients using atazanavir-based HAART reported in a multivariate analysis, an unexpected &#8220;protective effect&#8221; on lower bilirubin levels from HCV coinfection and in patients with a history of injecting drug use (IDU). Changes in bilirubin to week 12, and level at week 12, were the primary and secondary endpoints in the study.<\/strong><\/p>\n<p>Baseline characteristics of the 79 patients included 58% male, 56% white, 27% black. Mean (+SD) values for age was 35 [+7], CD4 count was 200 [+168] and HIV RNA 4.1 logs [+1.5]. Around 60% were IDU and HCV-positive. The review did not look at results of 14 patients who discontinued atazanavir before week 12.<\/p>\n<p>Mean [SD] bilirubin increase to week 12 was 16 [+16] mmol\/L. Factors associated with bigger changes and higher bilirubin at week 12 included baseline ALT, GGT, Alk Phos, methadone use, history of IDU, being white and HCV+. However in multiple regression, only HCV status and history of IDU were independently associated with change in and levels of bilirubin at week 12 (P &lt; 0.0001). Increase in bilirubin was lower; 12 [+13] mmol\/L for HCV+ versus 21 [+16] for HCV- (p=0.006); and 14 [+17] for IDU versus 21 [+15] mmol\/L for no IVDA (p=0.01).<\/p>\n<h3 class=\"comment\">Comment<\/h3>\n<p class=\"comment\"><strong>These finding are limited by small numbers and use of retrospective case notes. It is unclear whether, even if confirmed, this effect is significant enough to have a clinical significance.<\/strong><\/p>\n<p class=\"ref\">Reference:<\/p>\n<p class=\"ref\">Cotter A et al. Patients with HIV and hepatitis C co-infection experience less atazanavir-induced hyperbilirubinaemia. Poster 45.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base A retrospective case note review of patients using atazanavir-based HAART reported in a multivariate analysis, an unexpected &#8220;protective effect&#8221; on lower bilirubin levels from HCV coinfection and in patients with a history of injecting drug use &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[50],"class_list":["post-771","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-bhiva-14th-2008"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=771"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/771\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}